Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2020

In vivo effects of the CB1 allosteric modulator LDK1258, a
structural analog of ORG-27569
Mohammed A. Mustafa
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medical Pharmacology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/6277

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

© Mohammed A. Mustafa

2020

All Rights Reserved

1

In vivo effects of the CB1 allosteric modulator LDK1258, a structural analog of ORG27569

A dissertation submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University

by

Mohammed A. Mustafa
Bachelor of Science, Virginia Commonwealth University, 2015

Advisor: Aron H. Lichtman, PhD
Professor of Pharmacology and Toxicology
Virginia Commonwealth University

Virginia Commonwealth University
Richmond, VA
2020
2

Acknowledgements
First and foremost I would like to thank Dr. Aron Lichtman. My development as a
scientist has been profoundly influenced by your guidance and mentorship. You have
challenged my thinking, given me opportunities to develop valuable lab and
administrative skills, and supported me throughout my time as an undergraduate and
graduate student. In addition, you give me opportunities to attend conferences and
participate in writing collaborations which provide indispensable experience that
facilitates my growth in the career field of cannabinoid pharmacology. Your skills as a
scientist and overall genuine character are inspiring and I am grateful to have the
opportunity to work under your leadership.
To my master’s committee members Dr. Imad Damaj and Dr. Joseph Porter, the
input and guidance provided on this thesis project is very much appreciated and I would
like to thank you both. In addition, your expertise in behavioral pharmacology has
provided valuable discussions to facilitate the completion of this project and my overall
growth as a pharmacologist.
I give thanks to the entire faculty and staff of the Pharmacology and Toxicology
department who have supported and facilitated my development over the years.
Particularly, I would like to thank Dr. William Dewey, Dr. Krista Scoggins, Dr. Laura SimSelley, Dr. Dana Selley, and Dr. Joel Scholsburg for their guidance and mentorship. In
addition, I would like to specifically thank the lab members of the Lichtman Lab, past
and present, who have provided an enriching and positive environment to work in.
Specifically, I am grateful for the direct contributions that Dr. Giulia Donvito, Lauren
Moncayo, and Amelia Swafford have given towards this project.
In addition, I give many thanks to the Pharmacology and Toxicology Transgenic
Animal Core, particularly Dr. Jolene Windle and Dr. Pam Watters. Also thank you to the
Pharmacology and Toxicology Analytical Core, particularly Justin Poklis for the
facilitation of the analytical studies presented in this thesis. Also, many thanks to our
collaborators at the University of Connecticut and Texas A&M, Dr. Deb Kendall and Dr.
Dai Lu, respectively for all their contributions.
Lastly, I would like to thank my family and friends for the unconditional support
throughout the years as I embarked on my academic and career goals.

3

Table of Contents

Copyright page……………………………………………………………………………....... 1

Title page……………………………………………………………………………………….. 2
Acknowledgements……………………………………………………………………………. 3
Table of Contents……………………………………………………………………………… 4
List of Tables and Figures……………………………………………………………………. 5
List of Abbreviations………………………………………………………………………....... 6
Abstract…………………………………………………………………………………………. 7
Chapter I: General introduction………………..…………………………………………..… 10
Chapter II: In vivo evaluation of the CB1 allosteric modulator LDK1258 reveals CB1
receptor independent behavioral effects……………………………………………………. 25
Chapter III: Conclusions and discussion……………………..…………………………….. 47
List of References……………………………………..……………………………………… 56
Vita………………………………………………………………………………………………65

4

List of Tables and Figures

Table 1…………………………………………………………………………………………23
Table 2…………………………………………………………………………………………24
Table 3…………………………………………………………………………………………45
Table 4…………………………………………………………………………………………46

Figure 1……………………………………………………………………………………...…37
Figure 2…………………………………………………………………………………………38
Figure 3…………………………………………………………………………………………40
Figure 4…………………………………………………………………………………………42
Figure 5…………………………………………………………………………………………43
Figure 6…………………………………………………………………………………………44

5

List of Abbreviations

2-AG = 2-arachidonoylglycerol
AEA = N-arachidonoylethanolamine; anandamide
CB1 = Cannabinoid receptor type-1
CB2 = Cannabinoid receptor type-2
CCI = chronic constrictive nerve injury
CIPN = chemotherapy-induce peripheral neuropathy
FAAH = fatty acid amide hydrolase
GCPR = G-protein coupled receptor
HPLC-MS = high-pressure liquid chromatography/ mass spectrometry
MAGL = monoacylglycerol lipase
THC = delta-9-tetrahydrocannabinol

6

Abstract
IN VIVO EFFECTS OF THE CB1 ALLOSTERIC MODULATOR LDK1258, A
STRUTURAL ANALONG OF ORG-27569
Mohammed A. Mustafa, Bachelor of Science
A dissertation submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University
Virginia Commonwealth University, 2020
Advisor: Aron H. Lichtman, PhD, Professor of Pharmacology and Toxicology

Cannabinoid type-1 (CB1) receptor allosteric modulators are an area of growing interest
in the cannabinoid research field as novel experimental tools and a potential therapeutic
strategy. While the quantity of publications examining CB1 allosteric modulators has
substantially increased in recent years, most reports describe the cellular mechanisms
of these compounds and relatively few published studies have examined the in vivo
pharmacology of these compounds. ORG-27569 is a first-generation CB1 allosteric
modulator and the most widely studied to date. This compound enhances [3H]CP55,940
binding at the CB1 receptor in vitro (Price et al., 2005), but it’s in vivo effects are CB1
receptor independent (Gamage et al., 2014). Subsequent series of CB1 allosteric
modulators have been developed, many of which are structural analogs of the ORG27569 pharmacophore such as the novel compound LDK1258. The purpose of this
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thesis dissertation is to examine LDK1258 in in vivo models of neuropathic pain,
cannabimimetic side-effects, and feeding behavior.
Cellular studies of LDK1258 report that it shows a concentration dependent
inhibition of CP55,940-induced G-protein coupling activity with a KB value of 89.1 nM in
a [35S]GTPγS binding assay (Khurana et al., 2014). This compound was selected as the
candidate test compound because of its high binding affinity compared to other
structurally similar compounds. In a series of behavioral experiments in mice, we tested
LDK1258 in mouse assays sensitive to CB1 receptor stimulation, which include the
tetrad assay (comprised of measures assessing locomotor activity, catalepsy,
antinociception, and hypothermia), the drug discrimination paradigm, food consumption,
and the chronic constrictive sciatic nerve injury (CCI) model of neuropathic pain. In
addition, we tested whether this compound was CNS penetrant and if any active
metabolites were detectable following systematic administration in mice. When tested
alone in the tetrad assay, LDK1258 produced a significant decrease in locomotor
activity and body temperature, but not antinociception, as measured in the tail
withdrawal assay, or catalepsy, as assessed in the bar test. LDK1258 decreased
locomotor behavior and body temperature to a similar magnitude in CB1 (-/-) and (+/+)
mice, indicating CB1 receptor independent effects. Moreover, LDK1258 failed to shift the
dose-response curves of two orthosteric CB1 receptor agonists, CP55,490 in C57BL/6J
mice and AEA in FAAH (-/-) mice in the tetrad assay. In the mouse drug discrimination
assay, LDK1258 failed to substitute or shift the dose-response curve for either of these
agonists but dose-dependently suppressed response rates indicating a
pharmacologically relevant effect in this assay. Because mice administered the parent
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compound ORG-27569 show reduced food intake, we investigated whether LDK1258
affected food consumption and tested CB1 receptor dependency using CB1 (-/-) and
(+/+) mice. LDK1258 reduced food consumption regardless of genotype, again
indicating a CB1 receptor dispensable effect. In comparison, the CB1 receptor
antagonist rimonabant dose-dependently reduced food intake in CB1 (+/+) mice, but not
in CB1 (-/-) mice. In the final study, we examined LDK1258 in the CCI model of
neuropathic pain. Unexpectedly, it elicited a delayed antinociceptive effect (i.e.,
beginning at 4 h) that was CB1 receptor independent. The results of the studies
conducted throughout this thesis project demonstrate that LDK1258 decreases
locomotor activity, body temperature, and food consumption, as well as elicits a delayed
antinociceptive effect in the CCI model of neuropathic pain. However, the CB1 receptor
is not required for these pharmacological effects.
These findings underscore challenges in translating in vitro effects of newly
developed CB1 receptor allosteric modulators to the whole animal, as well as
emphasize the importance for medicinal chemists, structural biologists, cellular
pharmacologists, and behavioral pharmacologists to advance the development of CB1
receptor allosteric modulators. Additionally, we demonstrated the importance of using a
methodology that incorporates series of behavioral tests modeling neuropathic pain,
feeding behavior, and THC-like side effects as a model to assess the in vivo effects of
novel CB1 allosteric modulators.

9

Chapter I
General Introduction

A major step in understanding of the endocannabinoid system began when the primary
psychoactive constituent of the Cannabis sativa plant, Δ9-tetrahydrocannabinol (THC)
(Gaoni & Mechoulam, 1964) was identified and isolated. Subsequently, medicinal
chemists developed synthetic analogs of THC and conducted structure-activityrelationship studies of these novel compounds (Razdan, 1986). One analog, CP55,940
was tritium-labeled to a high specific gravity and used as a tool to facilitate the discovery
of the CB1 receptors (Devane et al., 1988) which were identified and cloned in human
brain (Matsuda et al., 1990). In later years, CB2 receptors were identified in peripheral
tissue (Munro et al.,1993). Both receptor types are described as being the primary
targets of THC.
CB1 receptor signal transduction. The CB1 receptor is predominantly
expressed on pre-synaptic axon terminals of neurons and is the most abundant GCPR
expressed in the central nervous system (CNS) (Alger & Kim, 2011). These receptors
are part of the rhodopsin-like family of 7-transmembrane spanning receptors and CB1
ligands bind within the central core formed by the interaction of the seven
transmembrane helices. They are Gi/o-coupled proteins that elicit downstream signaling
cascades when activated which allows for release of a G-protein subunit to regulate
effector proteins, ultimately dampening pre-synaptic neurotransmitter release (Mackie,
2006). Specifically, release of the G-protein subunit inhibits adenylyl cyclase activity
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resulting in an inhibition of cAMP accumulation. Intracellular cAMP and cAMPdependent protein kinase A (PKA) phosphorylate ion channels in neurons (Howlett &
Shim, 2013). When the CB1 receptor is activated intracellular cAMP concentrations
decrease resulting in inhibition of ion channel phosphorylation. This net reduction of ion
channel phosphorylation results in a hyperpolarization of axon terminals and a blunted
response to depolarizing stimuli (Howlett & Shim, 2013). Studies examining the effects
of CB1 agonists in transgenic animals indicate that CB1 receptor is responsible for the
behavioral effects of THC and other exogenous cannabinoids because these effects are
inhibited in CB1 (-/-) animals but not in (+/+) controls (Grim et al., 2016; Wiley et al.,
2005).
General introduction to the endocannabinoid system. Several endogenous
ligands that activate the CB1 receptor have been identified, with the two most
predominantly studied being N-arachidonoyl ethanolamine (anandamide; AEA) (Devane
et al., 1992) and 2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al.,
1995). These endogenous cannabinoids (endocannabinoids) function as retrograde
messengers that are released on demand from post-synaptic cells to modulate presynaptic neurotransmitter release (Mackie, 2006). AEA, 2-AG, and other
endocannabinoids are regulated by a distinct set of enzymes that modulate the
biosynthesis and degradation of these ligands. It is known that 2-AG is synthesized by
diacylglycerol lipases (DAGL-α and DAGL-β) (Bisogno et al, 2003). Alternatively,
evidence suggests NAPE-PLD activity regulates AEA biosynthesis but the mechanisms
mediating the production of AEA are incompletely understood (Blankman & Cravatt,
2013). Because of the rapid degradation of AEA and 2-AG by their respective metabolic
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enzymes, fatty acid amide hydrolase (FAAH) (Cravatt et al, 1996, 2001) and
monoacylglycerol lipase (MAGL) (Blankman et al, 2007; Dinh et al, 2002), these
endogenous ligands produce a short-lived duration of action.
In the simplest terms, the endocannabinoids in addition to the CB1 and CB2
receptors comprise the endogenous cannabinoid system (endocannabinoid system)
and are neuromodulatory regulators that affect various physiological processes
depending on cell type and location. Processes regulated by the endocannabinoid
system include, but are not limited to feeding behavior and energy storage (Wiley et al.,
2005), reward (Chen et al.,1991; Gardner et al.,1988; Lepore et al., 1996), stress
responses (Patel et al., 2017) and pain and inflammation (Guindon & Hohmann, 2012).
Exogenously administered cannabinoids, such as THC, affect these physiological
processes as well and can be used for therapeutic application.
Clinical use and side-effects of cannabinoids. Evidence of the therapeutic
effects of cannabinoids has been recorded as early as ~2700 BCE in ancient China with
the use of herbal cannabis for various ailments (Booth, 2003). In modern medicine,
dronabinol (THC) and nabilone (sold under the brand name Cesamet) are FDAapproved as antiemetics to reduce cancer chemotherapy associated nausea and
vomiting (Sallan et al., 1975; Poster et al., 1981). Dronabinol is also approved as an
appetite stimulator in patients afflicted with AIDS-related cachexia (Gorter et al., 1992).
It is important to note that despite the promise to treat various conditions, the
clinical utility of cannabis and other exogenous cannabinoid agonists are limited due to
their intoxicating effects, ability to impair cognitive function, and associations with
psychiatric conditions such as schizophrenia, acute anxiety, and cannabis use disorder
12

(Bhattacharyya et al., 2017; Foster et al., 2018; Ramaekers et al., 2009; Renard et al.,
2018). CB1 receptor antagonists, such as rimonabant, have also been developed as
therapeutics for weight loss; however, the availability of rimonabant for clinical use in
Europe was withdrawn and further evaluation was ceased due to severe side-effects
such as depression, anxiety disorder, and suicide ideation (Christensen et al., 2007;
Moreira & Crippa, 2009). These side effects of agonists and antagonists that bind the
orthosteric (i.e., active) binding site on the CB1 receptor limit the therapeutic utility of
these compounds.
CB1 allosteric modulators are hypothesized to offer clinical promise with minimal
side effects because they modulate and fine-tune the effects of endogenous ligands
already on board at the CB1 receptor site, rather than flooding the system with
exogenous ligands (Pertwee, 2005; Ross, 2007). In summary, modulation of the
endocannabinoid system which is comprised of CB1 and CB2 receptors and biosynthetic
and degradative enzymes which metabolize endogenous ligands holds promise as a
viable target for therapeutic development with a limited side-effect profile.
Introduction to CB1 allosteric modulators. Traditionally, the effects of CB1
receptors are regulated by agonists and antagonists of the primary binding site
(orthosteric site) which both endogenous and exogenous cannabinoids bind. The
ligands which occupy this site are referred to as orthosteric ligands. Because of adverse
side-effects listed above that are associated with orthosteric binding, alternative
approaches to targeting the CB1 receptor are currently being explored. One approach is
to utilize CB1 receptor allosteric modulators, which bind to topographically distinct sites
from the orthosteric site on the receptor (Kenakin, 2004; Kenakin & Strachan, 2018;
13

Khurana et al., 2014; Price et al., 2005; Ross, 2007). These compounds do not directly
activate the CB1 receptor, unlike orthosteric agonists, but rather bind to a secondary
(allosteric) site on the receptor, which results in a conformational change of the
receptor. Ligands making these conformational changes are conceptualized to enhance
(positive allosteric modulator, PAM) or decrease (negative allosteric modulator, NAM)
the efficacy and potency of orthosteric ligands that bind to the CB1 receptor which
include endogenous ligands (Kenakin, 2004). It is hypothesized CB1 allosteric
modulators offer therapeutic potential with reduced adverse side-effects compared with
orthosteric ligands (Kenakin, 2004) because these molecules may circumvent issues
with persistent orthosteric activation and may be more selective based upon the
orthosteric endogenous ligand present (Kenakin & Strachan, 2018).
Currently, benzodiazepines, which allosterically modulate GABAa receptors are
FDA-approved for the treatment of anxiety. These compounds potentiate the effect of
GABA and lack the potentially lethal adverse effects of GABAa agonists, such as
respiratory depression. The discovery and clinical success of benzodiazepines
demonstrates that allosteric modulation is a viable therapeutic strategy (Wenthur et al.,
2014). In comparison, no clinically approved allosteric modulators of CB1 receptors
currently exist. However, efforts have increased to synthesize and evaluate novel CB1
receptor allosteric modulators.
First generation CB1 allosteric modulators are defined as compounds with
chemical structures (pharmacophores) unlike that of previously reported compounds in
this class of drugs. First-generation compounds are either found endogenously such as
lipoxin A4 (Pamplona et al., 2012), or are synthesized by medicinal chemists such as
14

ORG27569 (Price et al., 2005). Other first-generation allosteric modulators of the CB1
receptor include PSNCBAM-1 and ZCZ011 (B. M. Ignatowska-Jankowska et al., 2015).
Second-generation CB1 allosteric modulators are defined as compounds which are
structurally similar to a first-generation compound but have an alteration of one or more
functional groups which affects the pharmacodynamic and pharmacokinetic properties
of the molecule. Both first- and second-generation CB1 allosteric modulators either
enhance or decrease the binding of orthosteric ligands. In addition, they alter
downstream signal transduction to either enhance or decrease orthosteric ligand
efficacy. Interestingly, effects on downstream signaling can be independent of
enhancement or decrease in binding. Although a growing body of research has
characterized the cellular pharmacology of CB1 receptor allosteric modulators, the
relatively few studies investigating the in vivo pharmacology of these ligands yielded
mixed results.
In vitro characterization of first-generation CB1 allosteric modulators. ORG27569 is a first-generation CB1 allosteric modulator developed by the pharmaceutical
company Organon (acquired by Schering-Plough Corporation in 2007) and is the most
extensively characterized compound in this class thus far. In initial in vitro studies
characterizing this compound (Price et al., 2005), ORG-27569 produced a significant,
but saturable, increase of orthosteric agonist binding in an equilibrium binding assay
using the radioligand probe [3H]CP 55,940. A binding cooperativity factor (α) denotes
the allosteric interaction between the orthosteric and allosteric ligands when they both
occupy the receptor, i.e., it quantiﬁes the direction of and magnitude by which the aﬃnity
of one ligand is changed by the other ligand when both are bound to the receptor to
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form the ternary complex (Christopoulos, A. et al., 2004). When α is 1.0, the test
modulator does not alter orthosteric ligand binding. If α is less than 1.0, the test
modulator reduces orthosteric ligand binding indicating negative allosteric modulation
(NAM). A compound with a binding cooperativity factor greater than 1.0, indicates
positive allosteric modulation (PAM) (Price et al., 2005). ORG-27569 had a binding
cooperativity factor greater than 1.0 when co-administered with [3H]CP 55,940 in mouse
brain membranes indicating PAM activity. In contrast, when the CB1 inverse agonist [3H]
SR141716A was co-administered with ORG-27569, the result produced a decrease in
the [3H]SR141716A equilibrium binding and binding cooperative value less than 1.0
indicating NAM activity when this probe was used (Price et al., 2005). Additionally,
dissociation kinetic experiments showed that ORG-27569 reduced CP55,940
dissociation from the receptor in mouse brain in vitro (Price et al., 2005). Whereas CB1
orthosteric agonists inhibit electrically evoked contractions of isolated mouse vas
deferens, ORG-27569 given alone lacked efficacy. However, ORG-27569 ameliorated
the actions of the CB1 receptor agonist WIN 55,212 in this functional CB1 receptormediated assay (Price et al., 2005). Additionally, ORG-27569 produced a rightward shift
of the dose response curves of CP55,940 and AEA in stimulation of [35S]GTPγS activity.
The effects of ORG-27569 in the isolated mouse vas deferens assay and [35S]GTPγS
activity assay are consistent with negative allosteric modulation (Price et al., 2005).
Lastly, studies examining the effects of ORG-27569 on luciferase expression by
CP55,940 in cloned human CB1 receptors expressed in Chinese hamster ovary cells
showed similar results to studies conducted using mouse CB1 receptors indicating that
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these effects were observable in cells expressing either human- or mouse- CB1 (Price et
al., 2005).
Because ORG-27569 did not produce agonist or inverse agonist properties
when tested alone in vitro, and modulation of receptor function was observed when the
receptor was dually occupied by both the orthosteric and allosteric compounds, these
results support the conclusion that ORG-27569 functions as an allosteric modulator of
the CB1 receptor in vitro (Price et al., 2005). It is important to note that, despite the
enhancement of orthosteric binding, which is consistent with PAM activity, this
compound produced a decrease of orthosteric agonist inhibition of electrically evoked
contractions in the mouse vas deferens model of measuring effects of CB1 activation
and agonist induced G-protein activity in the [35S]GTPγS binding assay (Price et al.,
2005). These findings suggest the functional effect of ORG-27569 in whole animal is
consistent with a NAM of the CB1 receptor, which results in a decrease of efficacy of
orthosteric agonists.
Another first-generation compound is the novel CB1 positive allosteric modulator
ZCZ011, which was synthesized at the University of Aberdeen (B. M. IgnatowskaJankowska et al., 2015). When tested in vitro, ZCZ011 produced significant and
concentration-dependent increases in the specific equilibrium binding of CB1 receptor
agonists [3H]CP55,940 and [3H]WIN 55,212 with an Emax of 207% and 225%,
respectively, as demonstrated by an equilibrium binding experiment in mouse brain
membranes (B. M. Ignatowska-Jankowska et al., 2015). Additionally, a saturation
binding experiment using mouse brain membranes and [3H]CP55,940 as the probe
demonstrated that ZCZ011 significantly increases the number of available CB1 binding
17

sites for the orthosteric agonist (B. M. Ignatowska-Jankowska et al., 2015). ZCZ011
also enhanced AEA stimulated [35S]GTPγS binding in mouse brain membranes
demonstrating an increase of G-protein activity compared to AEA administration alone.
Importantly, ZCZ011 did not stimulate [35S]GTPγS binding when administered alone,
suggesting that this compound is not acting as an orthosteric agonist at the CB1
receptor (B. M. Ignatowska-Jankowska et al., 2015). In the PathHunter hCB1 β-arrestin
Recruitment Assay ZCZ011 enhanced β -arrestin recruitment stimulated by AEA.
However, when tested alone ZCZ011 also produced an increase in β-arrestin
recruitment which was 35.9% that of maximal stimulation (B. M. Ignatowska-Jankowska
et al., 2015). Finally, an AlphaScreen Surefire ERK 1/2 phosphorylation assay was
utilized and ZCZ011 increased the potency of AEA in activating ERK1/2
phosphorylation in hCB1 receptor cells (B. M. Ignatowska-Jankowska et al., 2015). All
these effects observed in vitro, in addition to the in vivo effects of ZCZ011 which will be
subsequently described in the next chapter section of this thesis, demonstrate that
ZCZ011 acts as a positive allosteric modulator of the CB1 receptor.
A growing body of research has characterized the cellular pharmacology of CB1
receptor allosteric modulators (Table 1). Comparatively, there are relatively few studies
investigating the in vivo pharmacology of these ligands yielded mixed results, which will
be described in Table 2 and the section below.
In vivo characterization of CB1 allosteric modulators. Models used to assess
the effects of CB1 orthosteric ligands in vivo are also used to evaluate CB1 allosteric
modulation in vivo. The tetrad is an assay specifically used to measure cannabimimetic,
or THC-like, effects in rodents. It consists of four measures mediated by the CB1
18

receptor including locomotor activity, catalepsy, antinociception, and hypothermia (Little
et al.,1988). Co-administration of a CB1 allosteric modulator with an orthosteric agonist
is expected to produce an augmentation of the orthosteric dose-response curve in the
measures of this assay. However, no effect is expected in the tetrad assay when a CB1
allosteric modulator is administered alone, indicating CB1 receptor modulation.
Additionally, the mouse drug discrimination paradigm is a measure of discriminative
stimuli and is used to assess the subjective effects of CB1 orthosteric agonists.
Similarly, it is expected that co-administration of a CB1 allosteric modulator in this
paradigm results in an augmentation of the subjective effects of the orthosteric agonist
while producing no substitution for the CB1 mediated discriminative stimuli on its own. It
also has been demonstrated that CB1 PAMs produce antinociception in mouse models
of neuropathic pain (B. M. Ignatowska-Jankowska et al., 2015; Slivicki et al., 2018)
indicating that these models can be used to assess the therapeutic potential of CB1
allosteric modulators to treat pain and neuropathy. Additionally, antagonism of the CB1
receptor results in decreases of food intake (Christensen et al., 2007; Wiley et al.,
2005), therefore measures of food intake have been used to assess the effects of CB1
NAMs (Gamage et al., 2014; Horswill et al., 2007).
Behavioral studies demonstrate that ORG-27569 reduces food intake in mice.
Because these effects are observed in both wild-type mice and transgenic CB1 (-/-) mice
the reduction in feeding behavior caused by ORG-27569 is CB1 receptor independent
(Gamage et al., 2014). Additionally, the negative allosteric modulator PSNCBAM-1
reduced food intake in rats, indicating actions consistent with CB1 receptor antagonism
(Horswill et al., 2007). However, this study did not assess whether CB1 receptors
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mediated these anorectic effects. ORG-27569 also attenuates both cue- and druginduced reinstatement of methamphetamine and cocaine seeking behavior (Jing et al.,
2014). Again, CB1 receptor mediation was not assessed in this study by either using
transgenic animals that lack the CB1 receptor or with a pharmacological approach to
inhibit the behavioral effect observed, therefore it is unclear if this effect is CB1dependant. In addition, ORG-27569 does not augment the cataleptic, antinociceptive, or
hypothermic effects of AEA, CP55,940, or THC in the tetrad assay (Gamage et al.,
2014). These findings highlight the translational gap between the effects of CB1
allosteric modulators in cellular assays versus effects in the whole organism.
The endogenous anti-inflammatory mediator Lipoxin A4 represents the first
evidence of a CB1 allosteric modulator producing in vivo effects consistent with CB1
allosteric modulation in whole organisms (Pamplona et al., 2012). Specifically, lipoxin
A4 enhanced the pharmacological effects of AEA in both cellular and behavioral assays.
It also protected against β-amyloid induced performance deficits in the Morris water
maze, an assay indicative of memory and learning. It is known that AEA is
endogenously released for one week following β-amyloid treatment. The performance
deficit was prevented by co-treatment with lipoxin A4, and this effect was reversed with
the CB1 receptor antagonist rimonabant (Pamplona et al., 2012). This evidence
suggests that lipoxin A4 enhances the effect of endogenous AEA and the protection
against β-amyloid induced deficits are CB1 receptor dependent. These results are
consistent with the conclusion that lipoxin A4 acts as a CB1 receptor PAM in vivo.
The CB1 positive allosteric modulator, ZCZ011 was tested for antinociception and
cannabimimetic activity in vivo (B. M. Ignatowska-Jankowska et al., 2015). ZCZ011
20

administered alone did not elicit any activity in the tetrad or drug discrimination assays,
but when co-administered with AEA or CP55,940 it produced left-wards shifts of the
dose-response relationship of the CB1 agonists, indicating activity consistent with
positive allosteric modulation. Additionally, ZCZ011 did not produce conditioned place
preference or aversion in mice, suggesting that it lacks rewarding or aversive effects on
its own. ZCZ011 crosses the blood-brain-barrier to enter the CNS which was confirmed
by HPLC-MS analysis of blood and brain tissue from mice pretreated with ZCZ011
(Poklis et al., 2015). Lastly, ZCZ011 produced antinociception in the chronic-constrictive
nerve injury (CCI) model of neuropathic pain and partially reversed carrageenaninduced mechanical allodynia through a CB1 mechanism of action (B. M. IgnatowskaJankowska et al., 2015). The observations that ZCZ011 does not produce
cannabimimetic side-effects when administered alone, but does produce antinociception
suggests it has therapeutic potential to be used as an analgesic in the clinic. Another
study of ZCZ011 found that it attenuated somatic signs of THC withdrawal and blocked
NSAID-induced gastric hemorrhages in rodents (Trexler et al., 2019) suggesting its
therapeutic potential to treat cannabis use disorder and gastric inflammation. These
actions of ZCZ011 are consistent with the concept that CB1 allosteric modulators can
produce therapeutic effects without the cannabimimetic side-effects commonly
associated with CB1 receptor agonism.
A compound which is a structurally similar analog of ZCZ011, the CB1 positive
allosteric modulator GAT211 produces in vivo effects similar to its parent compound
(Slivicki et al., 2018). In the described study, GAT211 produced CB1 receptor mediated
antinociceptive effects in the mouse neuropathic pain model of chemotherapy induced
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peripheral neuropathy (CIPN), which did not undergo tolerance or withdrawal following
repeated administration, and did not elicit psychotomimetic effects associated with CB1
receptor allosteric agonists, suggesting in vivo actions consistent with CB1 receptor
allosteric modulation (Slivicki et al., 2018). The results of this study provides rational
that second-generation compounds derived from first-generation compounds are viable
therapeutic candidates that warrant further evaluation.
LDK1258: a second-generation allosteric modulator. We selected the ORG27569 pharmacophore as the focus of this thesis dissertation since it is the most widely
characterized compound in the class of CB1 allosteric modulators. Several analogs of
ORG-27569 have been assessed for binding affinity and allosteric activity (Khurana et
al., 2014) but have not been tested for in vivo activity. One compound in particular (12f),
also known with compound code LDK1258 (M.W. = 401.97 g/mol) has a strong
equilibrium disassociation constant value of 89 nM for the allosteric binding site and
binding cooperativity factor of 5, defining it as a CB1 PAM which enhances orthosteric
agonist binding affinity (Khurana et al., 2014). In contrast ORG-27569 behaved like a
efficacy NAM by decreasing CP55,940-stimulated [35S]GTPγS activity in vitro (Khurana
et al., 2014). These findings demonstrate that the in vitro actions of this novel compound
are similar to ORG-27569, however evaluation of this second-generation allosteric
modulator has not been conducted in vivo.
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Table 1.

Compound

ORG-27569

PSNCBAM-1

ZCZ011

Lipoxin A4

Molecular structure

In vitro effects
- enhances equilibrium binding of CP55,940
- decreases equilibrium binding of SR
141716A
- reduces CP55,940 dissociation from
receptor
- reversed inhibition of electrically evoked
contractions of mouse vas deferens by
WIN55,212
- inhibits CP55,940 and AEA stimulated
[35S]GTPγS activity
- inhibits stimulation of CB1 by CP55,940,
WIN 55,212, AEA, and 2-AG in yeast
reporter assay
- reversed binding stimulated by CP55,940
and AEA
- reversed AEA-induced inhibition of
forskolin-stimulated
cyclic
AMP
accumulation
- enhances equilibrium binding of CP55,940
and WIN 55,212
- increases number of available CB1 binding
sites
- enhances AEA stimulated [35S]GTPγS
activity
- increases β -arrestin recruitment
- increases potency of AEA to stimulate
ERK1/2phosphorylation
- enhances equilibrium binding of CP55,940
and WIN 55,212
- increased the potency of AEA in
decreasing forskolin (FSK)-induced cAMP
levels
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Table 2.

Compound

ORG-27569

In vivo effects

MOA

References

- reduces food intake
- attenuates cue- and druginduced reinstatement of
methamphetamine and
cocaine seeking behavior

- Reduction in food intake is CB1
independent
- Not assessed in study of cue- and
drug- reinstatement of
methamphetamine and cocaine
seeking behavior

(Ding et al.,
2014; Gamage
et al., 2014;
Jing et al.,
2014)
Horswill et al.,
2007

PSNCBAM-1

ZCZ011

Lipoxin A4

- reduces food intake

- Not assessed

- leftward shift of AEA and
CP55,940 DR in tetrad and
drug discrimination
- Antinociception in CCI
mouse model
- Attenuates THC
withdrawal
- Attenuates NSAIDinduced gastric
inflammation

-

- produces tetrad effects
alone
- enhances the effects of
AEA in tetrad
- protective against βamyloid induced spatial
memory impairment in
mice

IgnatowskaJankowska et
al., 2015

- CB1 Dependent

Pamplona et
al., 2012

- Not assessed
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Chapter II
In vivo evaluation of the CB1 allosteric modulator LDK1258 reveals CB1 receptor
independent behavioral effects

Hypothesis. CB1 allosteric modulators are viable therapeutic tools to treat
neuropathic pain or be used as appetite suppressants and produce their effects via a
CB1-mediated mechanism of action without adverse side-effects commonly associated
with orthosteric activation or blockade of the CB1 receptor. The therapeutic potential and
side-effect profile of these compounds are reliably evaluated in a series of assays which
have been previously used to evaluate CB1 orthosteric ligands in vivo.
Rationale. The purpose of this thesis project is to evaluate a novel CB1 allosteric
modulator in vivo in a series of assays to determine whether the selected compound
produces pharmacological effects in whole organisms, and whether these effects are
CB1 receptor mediated and consistent with the action of CB1 allosteric modulators.
Novel CB1 allosteric modulators serve as valuable tools to determine a methodology
that evaluates whether cellular effects of CB1 allosteric modulation translates to whole
organisms. In this chapter, the methodology of the assays employed and results from
the conducted experiments are reported.
Here, we investigated whether LDK1258 produces in vivo effects consistent with
those of a CB1 receptor allosteric modulator. Since previous studies demonstrated that
CB1 allosteric modulators produce antinociceptive effects in CCI or chemotherapyinduced allodynia models of neuropathic pain (B. M. Ignatowska-Jankowska et al.,
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2015; Slivicki et al., 2018) as well as reduce food intake (Ding et al., 2014; Gamage et
al., 2014; Horswill et al., 2007) in rodents, we tested whether LDK1258 alters either
mechanical allodynia in the CCI model of neuropathic pain or food consumption in fooddeprived mice. In a subsequent study, we quantified brain and blood levels of LDK1258
following intraperitoneal administration to examine whether it was brain penetrant. In
addition, we tested whether LDK1258 substitutes for CP55,940 in C57BL/6J mice or
AEA in transgenic mice lacking the primary anandamide degradative enzyme fatty acid
amide hydrolase (FAAH; Cravatt et al., 1996; Cravatt et al., 2001) in the drug
discrimination assay. Similar to previous studies examining CB1 receptor allosteric
modulators (Gamage et al., 2014; B. M. Ignatowska-Jankowska et al., 2015), we
examined whether LDK1258 elicits cannabimimetic effects in the tetrad assay (Little et
al., 1988), consisting of measurements of locomotor behavior, thermal nociception,
catalepsy, and body temperature. In order to infer whether CB1 receptors mediate
pharmacological effects observed in the assays described above, we employed a
genetic approach using CB1 (-/-) mice or a pharmacological approach using the CB1
receptor antagonist rimonabant. Finally, because it was reported that ZCZ011 produces
leftward shifts of the generalization dose-response curves of AEA and CP55,940 in the
drug discriminative assay as well as leftward shifts for thermal antinociception,
catalepsy, and hypothermia (B. M. Ignatowska-Jankowska et al., 2015), it can be
concluded that these measures are viable for detecting CB1 allosteric modulation in
animal models. Therefore, we tested whether co-administration of LDK1258 alters the
pharmacological effects of AEA or CP55,940 in these assays.
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Methodology
Animals
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine, USA) were used in
tetrad, and drug discrimination studies. Male FAAH (-/-) mice on a C57BL/6J background
(VCU transgenic core, Richmond, Virginia, USA) were used in the tetrad and drug
discrimination studies (see below). Male and female CB1 (-/-) and (+/+) mice backcrossed
on a C57BL/6J background (VCU transgenic core, Richmond, Virginia, USA) were used
in subsequent feeding, tetrad, and neuropathic pain studies.

Drugs
LDK1258 (compound 12f) and LDK1256 (compound 12d; used as internal
standard for UPLC-MS/MS analysis) were synthesized at the Rangel College of
Pharmacy Health Science Center at Texas A&M University (Kingsville, Texas, USA) as
previously described (Khurana et al., 2014). Anandamide, CP55,940, and rimonabant
(SR141716A) were supplied by the National Institute on drug abuse (NIDA) (Rockville,
Maryland, USA). All drugs were dissolved in ethanol (Pharmco Products Inc., Brookfield,
Connecticut, USA), Alkamuls-620 (Rhodia, Cranbury, New Jersey, USA), and saline
(0.73%), in a ratio of 1:1:18. Injections were given via the intraperitoneal (i.p.) route of
administration in a volume of 1 ml per 100 g of body mass.
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Chronic constrictive injury of the sciatic nerve (CCI) model of neuropathic pain
The surgical procedure for chronic constriction of the sciatic nerve was conducted
as described by Bennett & Xie (1988) with modifications (B. M. Ignatowska-Jankowska
et al., 2015). Mice were anesthetized with isoflurane and using aseptic procedures the
sciatic nerve was isolated and then loosely ligated. Sham surgery was identical, except
for ligating the nerve. Mechanical touch was used to assess baseline responses and the
development of allodynia after surgery using von Frey monofilaments (North Coast
Medical, Morgan Hills, CA), as previously described (Murphy et al., 1999). Mice were
unrestrained and placed in a Plexiglas cylinder (8 cm diameter, 15 cm height) on top of a
wire mesh screen. Von Frey calibrated microfilaments were applied to each hind paw and
the stimulus threshold that induced a response (defined as lifting, licking, or shaking of
the paw) was recorded. Following allodynia testing, thermal hypersensitivity was
assessed by placing mice on a hot plate analgesia meter (Columbus Instruments,
Columbus, OH) and latency to jump, shake, or lick the hind paw was recorded. LDK1258
(30 mg/kg) was injected via the i.p. route of administration and mice were tested for
mechanical and thermal allodynia at 0.5, 1, 2, 4, 6, 8, and 24 h in a time-course design.
This dose was selected based upon initial pilot studies. Treatments were administered
i.p. in a counterbalanced, between-subject design.

Food intake assay
Mice were housed in clear plastic cages with elevated wire mesh floors to allow for
food and feces to be out of reach of the mouse. Following a minimum of 72 h acclimation
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period, the mice were food deprived for approximately 24 h before receiving LDK1258,
rimonabant (control), or vehicle treatments. Following the deprivation period mice were
injected 15 min before receiving access to 15 (± 0.1) g of standard rodent chow (Teklad,
Madison, Wisconsin, USA). Food consumption was recorded in grams eaten 2 h after
food administration during the light-phase of a 12/12 h light/dark cycle. This procedure is
like those previously used in examining the consequences of cannabinoid receptor
agonists and antagonists on food consumption (Wiley et al., 2005). LDK1258 doses were
selected based upon initial pilot studies.

Ultra-performance liquid chromatography tandem mass spectrometer analysis of
LDK1258
Mice were given an intraperitoneal (i.p.) injection of vehicle or LDK1258 (30 mg/kg)
and were euthanized via cervical dislocation either 30 min or 4 h later. This dose was
selected because it produced robust behavioral effects when administered alone in the
tetrad, drug discrimination, food intake, and allodynia tests. Blood was collected by
breaking the skin with a needle prick from cheek tissue before euthanasia and whole
brains were collected immediately after sacrificing the animals. All samples were kept at
-80 C until analyzed. On the day of analysis, the brain tissue samples were weighed,
diluted 1:5 with water and homogenized. With each analytical analysis seven-point
calibration curves at concentrations of 50 - 5000 ng/mL LDK1258 for blood and 50 - 5000
ng/kg LDK1258 for brain tissue homogenate along with a drug free control and a control
without internal standard (ISTD) in drug-free mouse blood and brain tissue were
prepared. LDK1258 was extracted from blood and brain tissue homogenate using a
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liquid/liquid extraction (Poklis et al., 2010). In brief, 200 ng/mL or ng/g of LDK1256, the
ISTD, was added to 20 µL aliquots of blood or 100 µL aliquots of brain tissue homogenate
of each calibrator, control, or specimen except the negative control. 200 µL of acetonitrile
was then added to each of these sample and mixed for 2 min. The samples were then
centrifuged at 2054g for 5 min. After centrifuging the top layer containing the acetonitrile
was removed via a disposable glass pipette and placed in autosampler vial for analysis.
The ultra-performance liquid chromatography tandem mass spectrometer (UPLCMS/MS) analysis of was performed on a Sciex 6500+ QTRAP system with an IonDrive
Turbo V source for TurbolonSpray® (Sciex, Ontario, Canada) attached to a Shimadzu
UPLC system (Kyoto, Japan) controlled by Analyst software (Sciex, Ontario, Canada).
Chromatographic separation of LDK1258 and the internal standard, was performed using
a Thermo Hypersil Gold column, 50 x 2.1 mm, 3 micron (Waltham, MA). The mobile phase
contained water/methanol (10:90, v/v) with 0.1 mM ammonium formate and was delivered
at a flow rate of 1 mL/min. The source temperature was set at 650° C, and curtain gas
had a flow rate of 30 mL/min. The ionspray voltage was 5500 V, with the ion source gases
1 and 2 having flow rates of 60 mL/min. The declustering potential was 75 eV. The
quantification and qualifying transition ions with their collection energies in parenthesis
were monitored in positive multiple reaction monitoring (MRM) mode: 426> 192 (35) &
426 > 148 (25) for LDK1258 and 384> 220 (27) & 384> 148 (46) for the ISTD. The total
run time for the analytical method was 3 minutes. A linear regression of the peak area of
ratios of the quantification transition ions of LDK1258 and the ISTD were used to construct
the calibration curves.
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Drug discrimination
Separate groups of mice were trained to discriminate either anandamide (6 mg/kg)
or CP55,940 (0.1 mg/kg) from vehicle (30 min pretreatment time). One group consisted
of C57BL/6J mice trained to discriminate CP55,940, and the second group consisted of
FAAH (-/-) mice trained to discriminate anandamide. Training and testing were conducted
as previously reported (Ignatowska-Jankowska et al., 2015; Long et al., 2009; Owens et
al., 2016; Solinas et al., 2006; Walentiny et al., 2013). Sound-attenuating operant
conditioning boxes (MED Associates, St. Albans, VT) were used. Each apparatus
contained two nose-poke apertures (left and right) with a receptacle chamber located in
the middle of the apertures. A pellet dispenser delivered 14 mg sweetened pellets
following every 10th correct response. Nose pokes and food deliveries were recorded
using MED-PC IV software (MED Associates). Mice performed on a FR10 schedule of
reinforcement during each 15-minute training session. Training sessions were conducted
in a double-alternation sequence of drug and vehicle (e.g., vehicle, vehicle, drug, drug).
Test sessions were conducted twice per week with mice required to reach criteria to be
eligible for testing. Passing criteria were defined as follows: 1) the first 10 consecutive
responses on the correct apparatus side, 2) ≥ 80% of responses on the correctly paired
aperture, and 3) a response rate ≥ to 10 nose-pokes per min. During test sessions,
responses in either aperture resulted in delivery of the sweetened pellet according to the
schedule of reinforcement. Substitution tests were conducted by administering LDK1258
(3, 5.6, 10, 30 mg/kg) or vehicle i.p. 30 min prior to the test session when administered
alone. In the combination studies, LDK1258 (5.6 mg/kg) or vehicle i.p. was injected 15
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min before anandamide or CP55,940. This dose was selected because it was the highest
dose tested that did not produce rate-suppressive effects when administered alone. All
training drugs were administered subcutaneously. Mice were returned to their home cage
after each injection and were placed in the operant chamber immediately before the
beginning of the test session.

Tetrad assay
The tetrad assay consists of sequential testing for locomotor activity, catalepsy,
thermal antinociception, and body temperature (Little et al., 1988), as described below.

Locomotor activity assessment
The locomotor effects of LDK1258 were assessed by placing the mice in dimly lit
Plexiglas chambers (approx. 43 x 21 x 20 cm) for 300 s. The chambers were soundattenuated and equipped with a LED light source and a fan that provided air circulation
and white noise. Locomotor activity was monitored using Anymaze (Stoelting, Wood Dale,
IL) software, as described previously (Ignatowska-Jankowska et al., 2015). Distance
traveled, time immobile, and mean speed were recorded approximately 0.5 or 4.0 h after
LDK1258 or vehicle administration. Recordings were collected using Fire-i™ digital
cameras purchased from Unibrain (San Ramon, CA, USA).
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Bar test
Catalepsy was measured using the bar test, in which the mouse’s front paws were
placed on a metal bar 4.5 cm above the platform, and immobility time was measured for
a 60 s period. If the mouse removed its forepaws before 60 s elapsed, they were placed
back on the bar for a maximum of four tries. The test ended on the fifth attempt or once
60 s elapsed.

Warm-water tail-flick
Thermal nociceptive behavior was measured using the warm-water tail withdrawal
assay. The mouse was restrained and approximately 1 cm of the distal portion of the tail
was submerged in a 52° C water bath and the tail withdrawal latency was recorded. A 10
s cut-off was employed to prevent tissue damage if the mouse did not remove the tail
from the water in this period. In all experiments, tail withdrawal latencies are evaluated
prior to injection. Data were expressed as a maximum percent effect (%MPE) using the
following formula: %MPE = [(test latency – preinjection latency) / (10 – preinjection
latency)] ×100.

Body temperature
Hypothermic effects were assessed by inserting a thermometer probe (Physitemp
Instruments, Clifton, NJ) 2 cm into the rectum. For the LDK1258 and CP55,940
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cumulative-dose assessment in the triad assay, rectal temperature was measured using
an instrument from Traceable Products (Webster, TX). In all experiments, rectal
temperature was evaluated prior to injection. Body temperature data was expressed as a
change in temperature (° C) from pre-injection values.

Experimental procedure of tetrad assay
Four separate experiments were conducted to evaluate LDK1258 in the tetrad
assay. In the first two experiments, C57BL/6J mice were administered LDK1258 (30
mg/kg) or vehicle. In the first experiment, the mice tested for locomotor activity at 20 min
and in the second experiment, the mice were assessed for locomotor activity at 4 h.
Subjects were tested for locomotor behavior only once in order to avoid acclimation to the
chamber. Mice in the first experiment were tested for catalepsy, antinociception, and
hypothermia at 0.5, 1, and 2 h. Subjects in the second experiment were tested in these
respective measures at 4 and 6 h. The second experiment was conducted because of
unexpected delayed antinociceptive effects of LDK1258 in the CCI model. In the third
tetrad experiment, we evaluated lower doses of LDK1258 (3 or 10 mg/kg) in a new cohort
of mice. Drug- and vehicle-treated mice were evaluated for locomotor activity at 0.5 h.
Mice were assessed for each of the other measures at 0.5, 1, and 2 h. The fourth tetrad
experiment was conducted to determine whether CB1 receptors mediate the
pharmacological effects of LDK1258 in the tetrad assay. Accordingly, we evaluated
vehicle versus LDK1258 (30 mg/kg) in CB1 (+/+) mice versus CB1 (-/-) mice. Tetrad testing
proceeded identically as described for Experiment 1 above.
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Evaluation of LDK1258 on the dose-response relationships of CB1 receptor
orthosteric agonists in the triad assay
The in vivo cannabimimetic effects of LDK1258 were assessed in combination with
the CB1 orthosteric agonists anandamide in FAAH (-/-) mice or CP55,940 in C57BL/6J
mice. Measures of catalepsy, antinociception, and hypothermia were used for the triad
assay as previously described (Falenski et al., 2010; Grim et al., 2016). When tested in
combination with the cumulative-dose response of orthosteric agonists, LDK1258 (50
mg/kg) was administered 15 min prior to the first administration of anandamide or
CP55,940 followed by each subsequent dose every 40 min. Triad was assessed 30 min
following each anandamide or CP55,940 injection. Locomotor activity was not measured
in the cumulative-dose response assessments due to repeated testing causing
habituation effects. Because this assay is less sensitive than others, the highest dose of
LDK1258 that can be suspended in solution before reaching max saturation was selected.

Mouse hepatic microsome reaction
In order to investigate and identify metabolite(s), mouse hepatic microsomes were
isolated and prepared as previously described (Kessler & Ritter, 1997). Phase I
metabolism of LDK1258 and identification of potential p450 metabolites based on a
previously employed method (Poklis, Dempsey, et al., 2015). Briefly, 1 mL of medium
consisting of consisted of 167 mg total protein of pooled mouse hepatic microsomal
preparation, 50 mM Tris–HCl buffer, pH 7.4, 150 mM potassium chloride, 10 mM
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magnesium chloride with the addition of 0.4 mM freshly prepared NADPH and with or
without 100 µg LDK1258 were prepared. The mixtures were incubated in a 37° C water
bath for 60 min. The resultant p450 metabolites were isolated in ultrafiltrates using 30
kDa centrifugal filters (EMD Millipore, Billerica, MA, USA). An ultra-high-performance
liquid chromatography tandem mass spectrometer (UHPLC-MS/MS) was used to identify
potential metabolites from the exacted brain and blood samples.

Data analysis
All data are represented as mean ± S.E.M or 95% confidence limits (CLs). Data were
analyzed using GraphPad Prism 6.0, using either one-way or two-way analysis of
variance (ANOVA). Dunnett’s test was used for the post-hoc analysis. ED50 values,
potency ratios, and 95% CLs were calculated for the dose-response triad using linear
regression analysis (Colquhoun, 1971). Differences were considered significant if p <
0.05, or if the upper and lower confidence intervals of the potency ratios did not
encompass “1.”
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Experimental results

LDK1258 produces delayed antinociceptive effects in the chronic constriction
injury (CCI) model of neuropathic
As shown in Figure 1a, LDK1258 (30 mg/kg) reversed CCI-induced mechanical
allodynia in ipsilateral paw (F (8, 64) = 12.92, P < 0.0001) and contralateral paws (F (8,
64) = 17.65, P < 0.0001; data not shown) from 4 to 8 h. Likewise, LDK1258 (30 mg/kg)
reversed thermal hyperalgesia in the hot plate test from 2 to 8 h (F (8, 64) = 18.91, P <
0.0001; Figure 1b). The CB1 receptor antagonist rimonabant (3 mg/kg) did not block
LDK1258-induced antinociception in either assay (F (5, 18) = 83.43, P < 0.0001; Figure
1a and 1b).
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LDK1258 reduces food consumption in mice independently of the CB1 receptor
Subsequent experiments investigated the consequences of LDK1258 on food
intake in CB1 (-/-) and (+/+) mice following a 24 h fast. As CB1 (-/-) mice consumed less
food than CB1 (+/+) mice (t = 3.809, df = 56, P < 0.001; Figure 2a), drug effects on food
intake in each genotype were normalized as % intake of the vehicle-treated mice for each
genotype. Two-way ANOVA revealed that LDK1258 significantly reduced food intake to
a similar magnitude in both genotypes (LDK1258 main effect: F (3, 54) = 3.284, P < 0.05;
no genotype main effect: p = 0.54; no LDK1258 by genotype interaction: p = 0.30; Figure
2b). In comparison, rimonabant significantly reduced food intake in CB 1 (+/+) mice, but
not in CB1 (-/-) mice (genotype main effect: F (1, 26) = 26.42 P < 0.0001; no rimonabant
main effect: p = 0.19; no rimonabant by genotype interaction: p = 0.58; Figure 2c).
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Evaluation of LDK1258 in the mouse drug discrimination paradigm
LDK1258 (3-30 mg/kg) did not substitute for the discriminative stimulus of
anandamide (6 mg/kg) in FAAH (-/-) mice or CP55,940 (0.1 mg/kg) in C57BL/6J mice at
30 min post-injection (Figure 3a), but reduced response rates at the highest dose tested
in FAAH (-/-) mice (F (5, 46) = 24.36, P < 0.0001; Figure 3b) and in C57BL/6J mice (F (5,
52) = 28.07, P < 0.0001; Figure 3b). At 4 h post-administration of LDK1258 (30 mg/kg)
no significant effects on the discriminative stimulus or response rates occurred (data not
shown). We next evaluated whether LDK1258 would affect the generalization doseresponse relationships of anandamide in FAAH (-/-) mice and CP55,940 in C57BL/6J
mice. Accordingly, we selected the highest LDK1258 dose (i.e., 5.6 mg/kg) that did not
reduce response rates when administered alone. LDK1258 did not alter the generalization
dose response curve of either anandamide (1 – 6 mg/kg) or CP55,940 (0.01 – 0.1 mg/kg;
Figure 3c) or response rates (Figure 3d).
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Evaluation of LDK1258 in the tetrad assay
The tetrad assay was conducted in a series of four experiments (see Section 2.7.5
above). Experiments 1 and 2 are shown on the same graphs Figure 4). In the first
experiment LDK1258 (30 mg/kg) significantly reduced distance traveled (t = 4.96, df = 14,
P < 0.001; Figure 4a) and time immobile (t = 3.92, df = 14, P < 0.01; Figure 4b) at 20 min.
In this same experiment, the drug significantly increased catalepsy (LDK1258 main effect:
F (1, 42) = 5.518; P < 0.05) and tail-withdrawal latencies (LDK1258 main effect: F (1, 42)
= 16.40; P < 0.001), though the magnitude of these effects was small (see Figure 4c-d).
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LDK1258 also reduced rectal temperature up to 2 h (LDK1258 main effect: F (1, 42) =
38.35; P < 0.0001; Figure 4e).
The second experiment was conducted in a separate group of mice that were
tested 4-6 h after drug administration. LDK1258 (30 mg/kg) did not affect distance
traveled, time immobile, catalepsy, or tail-withdrawal latencies at these time points, but
did produce hypothermia from 4-6 h (LDK1258 main effect: F (1, 20) = 9.396; P < 0.01,
Time main effect: F (1, 20) = 5.125; P < 0.05; Figure 4e).
In the third experiment, we examined the effects of 3 and 10 mg/kg LDK1258 in a
separate group of mice in the tetrad assay. At these doses, LDK1258 did not affect
distance traveled or time immobile (Supplemental Figure 1a-b). In addition, LDK1258 did
not affect catalepsy or antinociception at these doses (data not shown), but it significantly
decreased body temperature up to 2h (LDK1258 main effect: F (2, 54) = 10.72; P < 0.001,
Supplemental Figure 1c).
We next employed CB1 (-/-) and (+/+) mice to examine whether CB1 receptors
mediate the locomotor and hypothermic effects of LDK1258. LDK1258 (30 mg/kg)
reduced distance traveled (LDK1258 main effect: F (1, 26) = 28.18, P < 0.0001) as well
as time spent immobile (LDK1258 main effect: F (1, 26) = 16.58, P < 0.001), irrespective
of genotype, indicating CB1 receptor independent effects. The CB1 (-/-) mice showed a
phenotypic decrease in locomotor behavior (main effect of genotype for distance: F (1,
26) = 5.54, P < 0.05; Figure 5a); main effect of genotype for immobility time: F (1, 26) =
4.46; P < 0.05; Figure 5b). Significant main effects LDK1258 (F (1, 26) = 6.870; P < 0.05)
and genotype (F (1, 26) = 4.759; P < 0.05; Figure 5c) were also found for tail withdrawal
latencies, though the magnitude of these was very small. Lastly, significant effects of
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LDK1258 (F (1, 26) = 55.61; P < 0.0001) and genotype (F (1, 26) = 7.73; P < 0.05; Figure
5d) were found for the hypothermia measure. Again, this drug effect was CB 1 receptor
independent. Figure 5 c and 5d depicts the 1 h tail-withdrawal latency and hypothermia
data. No significant effects were found in the catalepsy test (data not shown).
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Evaluation of whether LDK1258 alters the dose-response relationships of
orthosteric agonists in the triad assay
In the final series of experiments, we investigated whether LDK1258 (50 mg/kg)
would alter the cumulative dose-response relationship of anandamide (2.5 – 50 mg/kg) in
FAAH (-/-) mice or CP55,940 (0.1 – 1 mg/kg) in C57BL/6J mice in measures of catalepsy,
antinociception, and rectal temperature. As shown in Figure 6, LDK1258 failed to affect
the dose-response relationships of each orthosteric CB1 receptor agonist. The respective
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ED50 values of anandamide or CP55,940 did not differ between groups pretreated with
LDK1258 or vehicle, and potency ratio calculations verified the lack of an LDK1258 effect
on the potency of each orthosteric agonist (Table 3).
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Table 3.

Detection of LDK1258 in mouse blood and brain tissue
To determine whether LDK1258 brain and blood levels, we quantified drug levels in
mouse blood and brain tissue at 0.5 and 4 h after administration. LDK1258 (30 mg/kg;
i.p.) resulted in brain and blood levels detectable at both time points (Table 4). No drug
was detected in the brains or blood of vehicle-treated mice. Statistical analysis releveled
no significant changes in LDK1258 levels between these time points in each respective
tissue (n = 5-6 mice per group).
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Table 4.

Time (h)

Whole Brain (ng/g)

Blood (ng/mL)

mean +/- SEM

mean +/- SEM

0.5

35.5 (± 7.2)

352.5 (± 104.3)

4

43.2 (± 1.8)

174.4 (± 63.3)

Evaluation of LDK1258 metabolites in a mouse hepatic microsomal reaction
As the delayed effects of the LDK1258 may have resulted from the formation of an active
metabolite or metabolites, we used UHPLC-MS/MS on blood and brain tissue described
above to screen and identify potential metabolites. No P450 metabolites were detected
in the samples from either the 0.5 h or 4 h collection time-point (data not shown).
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Chapter III
Conclusions and Discussion

The results presented in this thesis dissertation represent the first study to
investigate LDK1258, a novel analog of the well-characterized CB1 allosteric modulator
ORG27569, in established in vivo assays highly sensitive to CB1 receptor activity.
Although several other structurally similar analogs of ORG-27569 have been developed
in recent years (Khurana et al., 2014), few studies have evaluated whether the effects of
these analogs translate from in vitro assays to the whole animal. CB1 allosteric modulators
developed in recent years utilize the pharmacophores of first-generation compounds and
have similar cellular and behavioral effects to their parent compounds (Gamage et al.,
2017; Slivicki et al., 2018). For the purpose of this thesis study we elected to focus on
one candidate compound and evaluate LDK1258 because of its high binding cooperativity
factor and strong equilibrium disassociation constant compared with other structurally
similar compounds (Khurana et al., 2014).
Summary of results. We report that HP-LCMS analysis of blood and brain tissue
of mice pretreated with LDK1258 reveals that this compound crosses the blood-brain
barrier to enter the CNS. A battery of in vivo experiments used in our methodology reveal
that LDK1258 produces behavioral effects, including hypolocomotion, hypothermia,
decreases in food intake, and delayed anti-allodynia in mice. These pharmacological
effects persisted in wild type mice administered the CB1 receptor antagonist rimonabant
or CB1 (-/-) mice, indicating actions inconsistent with that of CB1 receptor allosteric
modulation. Surprisingly, LDK1258 produced a delayed antinociceptive effect in the CCI
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model beginning at 4 h post-administration. This delayed response is different from the
onset of action of other CB1 positive allosteric modulators. For example, the
antinociceptive effects of the CB1 PAM ZCZ011 emerged within 30 min (B. M.
Ignatowska-Jankowska et al., 2015). Although the reason for the delayed onset of action
found here remains unknown, it is noteworthy that LDK1258 was detected in whole brain
at similar concentrations at 0.5 and 4 h. While a delayed onset of behavioral effects has
not been reported in studies examining other CB1 allosteric modulators, inhibitors of
biosynthetic and degradative endocannabinoid enzymes similarly display peak
antinociceptive effects at 1-3 hrs post-administration (Ignatowska-Jankowska et al., 2015;
Wilkerson et al., 2016). It is possible that LDK1258 has off-target effects, such as acting
on an enzyme or being metabolized into an active metabolite which are mediating the
delayed onset of antinociceptive effects. To determine whether metabolites were present
following LDK1258 administration we used a mouse hepatic microsomal assay which
modeled the P450 pathway. Although no metabolites were detected in mouse brain and
blood samples treated with LDK1258, this lack of finding does not rule out the possibility
that the delayed activity resulted from unidentified metabolites from a non-P450 metabolic
pathway. Lastly, the observation that the CB1 receptor antagonist rimonabant did not
block the delayed antinociceptive response suggests a CB1 receptor independent
mechanism.
Previous studies demonstrated that ORG27569 and PSNCBAM-1 decreased food
intake in rodents; however, the effects were either CB1-receptor independent or receptor
mechanism of action was not examined (Ding et al., 2014; Gamage et al., 2014; Horswill
et al., 2007). Similar to these first-generation CB1 allosteric modulators, LDK1258
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reduced food consumption in food-deprived mice. In order to provide a positive control
for the reduction in feeding behavior it was necessary to test a compound that is known
to suppress food intake via CB1. Therefore, we also replicated the finding that rimonabant
reduces food intake in CB1 (+/+) mice, but not in CB1 (-/-) mice (Gamage et al., 2014;
Wiley et al., 2005). However, LDK1258 produced anorectic effects regardless of genotype
indicating a CB1 receptor dispensable effect. Similarly, ORG-27569 reduced food intake
in CB1 (+/+) and (-/-) mice (Gamage et al., 2014). Thus, the anorectic effects of these
structurally related ligands occur through a CB1 receptor independent mechanism. On the
other hand, human subjects smoking cannabis in a laboratory setting increased snack
food consumption (Foltin et al., 1988). Moreover, as gavage administration of THC in rats
led to increased consumption of palatable food (Williams et al., 1998), it would be
worthwhile to assess effects of LDK1258 or CB1 allosteric modulators on consumption of
palatable food. However, this model of assessing food intake of standard chow in rodents
has been established to be sensitive to CB1 orthosteric ligands
In the tetrad assay, LDK1258 reduced locomotor activity and body temperature,
and produced small, but significant effects on catalepsy and thermal antinociception
measures. CB1 (-/-) mice showed a similar pattern of pharmacological effects indicating
a CB1 receptor independent mechanism of action. Similar to ORG-27569 (Gamage et al.,
2014), LDK1258 failed to alter the dose response curves of the high-efficacy CB1 receptor
agonist CP55,940 and the low-efficacy CB1 receptor agonist AEA in producing thermal
antinociception, catalepsy, and hypothermia. Prior studies have demonstrated the utility
of the mouse drug discrimination paradigm in detecting in vivo pharmacological effects of
the CB1 PAM ZCZ011 (B. M. Ignatowska-Jankowska et al., 2015). Here, LDK1258 did
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not alter the generalization dose-response relationships of AEA or CP55,940 in the drug
discrimination paradigm, though it reduced response rates (i.e. number of nose pokes per
min). Similarly, ORG-27569 did not alter the dose-response relationships of CB1 receptor
orthosteric agonists in the drug discrimination paradigm (Gamage et al., 2014). Thus,
assays previously shown to detect in vivo pharmacological effects of ZCZ011 (B. M.
Ignatowska-Jankowska et al., 2015) were negative for ORG-27568 (Gamage et al., 2014)
and LDK1258 (present results).
Limitations. A limitation of the current study is that we did not evaluate the
mechanism of action of effects that were shown to be CB1 receptor independent. For
example, it was not tested whether non-CB1 targets, such as CB2 or mu-opioid receptors,
mediate the delayed antinociceptive effect of LDK1258. Additionally, we did not evaluate
whether non-CB1 mechanisms of action were responsible for the reductions in food
intake, locomotor activity, and body temperature; effects that are consistent with the
actions of serotonergic drugs. Therefore, this study was limited in determining the
mechanism of action of these effects by not testing drugs that target CB2, mu-opioid, 5HT receptors, or other possible off-target sites. Effects on endocannabinoid tone was not
evaluated in this study, presenting another limitation and leaving undetermined the
possibility that LDK1258 is either decreasing or enhancing endocannabinoid tone via
inhibition of biosynthetic or degradative enzymes.
It is worthwhile to note that although previous studies have examined the doseresponse relationship of CB1 agonists when co-administered with a CB1 allosteric
modulator in the tetrad and drug discrimination assays (Gamage et al., 2014; B. M.
Ignatowska-Jankowska et al., 2015; Pamplona et al., 2012), an effect in these models
50

has only been demonstrated for positive allosteric modulation of the CB1 receptor (B. M.
Ignatowska-Jankowska et al., 2015; Pamplona et al., 2012). Comparatively, no significant
effect was detected in studies evaluating ORG-27569 (Gamage et al., 2014) or its analog
LDK1258 in the tetrad or drug discrimination assays, which were expected to cause
rightward shifts of the dose-response relationship of CB1 agonists due to their inhibition
of G-protein signal transduction pathways that mediate cAMP accumulation and ion
channel phosphorylation. This inability to alter the effects of orthosteric ligands in these
models for compounds expected to have CB1 NAM activity raises the possibility that the
tetrad assay and drug discrimination paradigm may be limited to detecting the effects of
CB1 positive allosteric modulation but not CB1 negative allosteric modulation.
Studies within this thesis examining food consumption may be limited in their
interpretation due to the fact that mice were food-deprived for 24 h prior to testing.
Determining the baseline food consumption of free-fed mice following drug administration
would have greater therapeutic and translational relevance since human subjects are not
normally food-deprived for long periods of time. It has been reported that cannabinoid
receptors modulate the consumption of palatable food in rodents (Amancio-Belmont et
al., 2017), therefore the use of standard rodent chow rather than palatable food is another
limitation of the present study.
Additionally, sham animals were not used for the CCI studies which presents a
limitation in the proper controls. It is possible that LDK1258 acts differently in animals who
receive CCI surgery versus sham animals that are not in an injured state. Using a
pharmacological approach to determine CB1 receptor mediation of the delayed
antinociceptive effects in the CCI model presents another limitation of the present study.
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It is important to note that previous observations that ZCZ011 significantly increases
specific binding of CP55,940 and WIN55,212-2, but reduces rimonabant CB1 receptor
binding (B. M. Ignatowska-Jankowska et al., 2015) questions the utility of employing CB1
orthosteric antagonists to infer receptor mediation of CB1 allosteric modulators. To
address this limitation, transgenic animals lacking the CB1 receptor should be used to
assess CB1 receptor mediation. Nonetheless, rimonabant blocked the antinociceptive
effects of ZCZ011 in the CCI model of neuropathic pain (B. M. Ignatowska-Jankowska et
al., 2015). Moreover, the CB1 receptor antagonist AM251 blocked the antinociceptive
effects of GAT211 in the paclitaxel model of neuropathic pain (Slivicki et al., 2018).
Another limitation is that we used a mouse hepatic model of the P450 pathway only. It is
possible that LDK1258 is metabolized by a different pathway which may produce active
metabolites. Lastly, it is unclear the extent to which LDK1258 may act as an ago-allosteric
modulator or a probe-dependent allosteric modulator that requires the orthosteric site to
be occupied (Ahn et al., 2012).
Future directions. The results indicating LDK1258 has antinociceptive and
anorectic properties provides rational for further investigation of LDK1258 to determine
whether this compound holds therapeutic promise to treat neuropathic pain or as an
appetite suppressant in models not utilized in the present study such as the
chemotherapy-induced peripheral neuropathy (CIPN) mouse model and operant
behavior assays which utilize palatable food. The observation that this compound
decreases locomotion, hypothermia, and food intake via a non-CB1 receptor mechanism
of action raises the need for future studies to examine the receptors and/or
neurotransmitter systems involved in mediating these effects. One approach to answer
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this question would be to utilize a pharmacological approach by testing various
antagonists of receptor systems that also mediate locomotion, body temperature, and
feeding behavior. For example, these physiological processes are also affected by
serotonergic compounds. Therefore, examination of a non-selective 5-HT receptor
antagonist may result in an inhibition of these LDK1258 effects. An alternative method
to identify the mechanism of action of the off-target effects of LDK1258 is to utilize a
Basic Alignment Search Tool (BLAST) protocol which is an algorithmic program that can
screen for binding selectivity of novel compounds against various GCPRs. In addition,
effects on biosynthetic or degradative enzymes should be assessed. Future studies that
examine brain levels of AEA, 2-AG, and other endogenous ligands are necessary to
determine if LDK1258 treatment has any effect on endocannabinoid levels in the CNS.
Future studies should also consider the limitation presented in this thesis by
using a pharmacological approach, rather than a genetic approach, to test CB1 receptor
mediation of the delayed antinociceptive effects in the CCI mouse model. This limitation
is presented by the observation that ORG-27569 and ZCZ011 decreases the binding of
the CB1 receptor inverse agonist rimonabant in vitro (B. M. Ignatowska-Jankowska et
al., 2015; Price et al., 2005), therefore it is possible that co-administration results in a
decrease of rimonabant binding in vivo. Subsequent studies of the antinociceptive
effects of LDK1258 should utilize transgenic CB1 (-/-) mice to confirm that the delayed
antinociceptive effect are indeed CB1 receptor independent. In addition, a full doseresponse of LDK1258 in addition to including a sham surgery control group should be
considered in any future assessments of this compound in the CCI model.
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Lastly, other non-P450 hepatic metabolic pathways may be contributing to the
metabolism of LDK1258 and should be investigated. Further collaboration with
medicinal chemists may result in the isolation and resynthesis of active metabolites
which may hold therapeutic potential.
Final conclusions. The ORG-27569 pharmacophore represents one of the most
widely used by medicinal chemists in the development of novel CB 1 allosteric modulators.
Interestingly, ORG-27569 increases CB1 receptor binding of CP55,940, while dampening
functional receptor responses (Price et al., 2005). Increased rates of CB1 desensitization
that concomitantly cause cAMP levels and hyperpolarization states to return to baseline
more rapidly than in the absence of the modulator may contribute to this paradoxical
response (Cawston et al., 2013). In comparison, LDK1258 displays actions similar to
ORG-27569 by enhancing agonist binging in radioligand binding assays and decreasing
functional responses in vitro (Khurana et al., 2014). Although the in vitro effects of ORG27569 and LDK1258 are consistent with CB1 allosteric modulation, these actions do not
translate to their in vivo actions, which are CB1 receptor independent.
Collectively, the studies conducted within this dissertation demonstrate a
translational gap from the cellular level to the whole organism in the development of CB 1
receptor allosteric modulators. In comparison, studies examining the structurally related
CB1 PAMs, ZCZ011 and GAT211, in in vivo assays show CB1 receptor dependent
pharmacological effects (B. M. Ignatowska-Jankowska et al., 2015; Slivicki et al., 2018).
ZCZ011 produces leftward shifts of the dose-response relationships of AEA and
CP55,940 in the triad and drug discrimination assays consistent with the action of a CB 1
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PAM; thus, demonstrating the utility of these assays in evaluating CB 1 allosteric
modulators.
The results of the present dissertation demonstrate that the novel CB1 allosteric
modulator, LDK1258, produces effects inconsistent with CB1 receptor allosteric
modulation and produces CB1 independent effects in vivo. A major contribution of this
study is that the methodology employed provides an efficient screen to evaluate the
behavioral effects of novel purported CB1 allosteric modulators. These results along with
studies evaluating the in vivo effects of ORG-27569 (Gamage et al., 2014), ZCZ011 (B.
M. Ignatowska-Jankowska et al., 2015), and their analogs (Slivicki et al., 2018; present
study) underscore the importance of screening purported CB1 allosteric modulators in
rodent models. Future development of the next generation of CB1 allosteric modulators
will require the combination of medicinal chemistry, cellular pharmacology, and behavioral
pharmacology and close collaboration between these fields.
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